Респираторная медицина. Руководство (в 2-х томах) - Чучалин А. Г.. Страница 52
51. Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J Asthma. 2006 Dec;43(10):765-72.
52. Selroos O, Edsbacker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma. 2004;41(8):771-90.
53. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70(4):288-98.
54. Boudinot FD, D'Ambrosio A, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm 1986; 14:469-493.
55. Masoli M., Holt S., Weatherall M., Beasley R. Dose-response relationship of inhaled budesonide
56.in adult asthma: a meta-analysis. Eur Respir J 2004; 23: 552 - 558.
57. Holt S, Suder A, Weatherall M et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:1 - 8
58. Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J Endocrinol. 2003 Dec;179(3):301-10.
59. Pedersen, S., and O. R. Hansen. 1995. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. 95:29 - 33.
60. Alving, K., J. O. N. Lundberg, and S. L. Nordvall. 1995. Dose-dependent reduction of exhaled nitric oxide in asthmatic children by in haled steroids (abstract). Am. J. Respir. Crit. Care Med. 151:A129.
61. Malmstrom, K, Rodriguez-Gomez, G, Guerra, J, et al Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130,487-495
62. Phillipps GH, Bailey EJ, Bain BM, et al. Synthesis and structure-activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17beta-carbothioates and -17beta-carboselenoates. J Med Chem 1994; 37:3717 - 3729
63. Belvisi M, Bundschuh D, Stoeck M, et al. Ciclesonide, a novel on site activatedinhaled corticosteroid with potent anti-inflammatory actions in the airways [abstract]. J Allergy Clin Immunol 2002; 109(suppl):59
64. Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60:330 - 337
65. Systematic Review of the Evidence Regarding Potential Complications of Inhaled Corticosteroid Use in Asthma. Chest 2003;124;2329-2340
66. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK: Frequency of voice problems and cough in patients using pressurised aersosol inhaled steroid preparations. Eur. Respir. J. 1995; 8:590-592.
67. Toogood JA, Jennings B, Greenway RW, Chung L: Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 1980; 65:145-153.
68. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine. 2000;343:1054-1063.
69. Agertoft L, et al. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New England Journal of Medicine. 2000;343:1064-1069.
70. Poolson JB, Kazanowski JJ, Goldman AL, Szentivanyi A: Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin. Exp. Pharmacol. Physiol. 1978; 5:535-539.
71. Pauwels RA, Joos GF: Characterization of the adenosine receptors in the airways. Arch. Int. Pharmacodyn. Ther. 1995; 329:151-156.
72. Ishizaki T, Minegishi A, Morishita A, et al: Plasma catecholamine concentrations during a 72 hour aminophylline infusion in children with acute asthma. J. Allergy Clin. Immunol. 1988; 92:146-154.
73. Horrobin DF, Manku MS, Franks DJ, Hamet P: Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins 1977; 13:33-40.
74. Spatafora M, Chiappara G, Merendino AM, D’Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur. Respir. J. 1994; 7:223-228.
75. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos Ch: Aminophylline improves diaphragmatic contractility. N. Engl. J. Med. 1981; 305:249-252.
76. Jusko WJ, Gardner MJ, Mangiore A, Schentag JJ, Kopp JR, Vance JW: Factors affecting aminophylline clearance: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. J. Pharm. Sci. 1979; 68:1358-1366.
77. Аharony D. Pharmacology of leukotriene receptor antagonists. // Am. J. Respir. Crit. Care Med. - 1998 Jun. - V. 157, 6 Pt 2. - P. 214-218
78. Devillier P., Millart H., Advenier C. The anti-leukotrienes: their use in asthma. // Rev. Med. Brux. - 1997 Sep. - V. 18, 4. - P. 279-285.
79. Drazen J.M. Pharmacology of leukotriene receptor antagonists and 5-lipoxigenase inhibitors in the management of asthma. // Pharmacotherapy. - 1997 Jan. - V. 17, 1 Pt 2. - P. 22-30.
80. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997 Feb;111(2 Suppl):27S-34S
81. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995;9:619 - 625.
82. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005 Apr;27(4):377-92.
83. Somand H, Remington TL. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Ann Pharmacother. 2005 Sep;39(9):1467-75. Epub 2005 Jul 19.
84. Proskocil BJ and Fryer AD бета2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease. Proc Am Thorac Soc Vol 2. pp 305 - 310, 2005
85. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34(33):10474 - 82.
86. Boushey H. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001;108(2 Suppl):S79
87. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-10482.
88. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269:26368-26373.
89. Sechi S, Roller PP, Willette-Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem. 1996;271:19256-19263.
90. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-162.
91. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308-312.
92. Schmidt D, Watson N, Reulmann E, Magnussen H, Rabe KF. Serum IgE levels predict human
93.airway reactivity in vitro. Clin Exp Allergy 2000;30(2):233 - 41.
94. Brownell J, Casale TB Anti-IgE therapy. Immunol Allergy Clin N Am 24 (2004) 551 - 568
95. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergeninduced early asthmatic response. Am J Respir CritCare Med 1997;155(6):1835 - 40.
96. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184 - 90.
97. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Review). The Cochrane Library 2007, Issue 1